CompositionMetformin (500mg),Pioglitazone (15mg)
SALT INFORMATIONMetformin (500mg) TYPICAL USAGE Diabetes mellitus, Hyperlipoproteinaemia, Insulin dependent diabetes mellitus, Insulin resistance, Non-insulin dependent diabetes mellitus, Obesity. SIDE EFFECTS Vasculitis, Pneumonitis, Malabsorption of vit B12, Malabsorpton of folic acid, Megaloblastic anemia, Hypoglycemia. DRUG INTERACTION Additive effect with sulphonylureas. Glycaemic control may be affected by diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens. MECHANISM OF ACTION The exact mechanism of action of metformin is unclear but it appears to reduce glucose absorption from the GI tract, reduce gluconeogenesis and enhance insulin sensitivity by increasing peripheral glucose uptake and utilisation. Pioglitazone (15mg) TYPICAL USAGE Diabetes mellitus type-II, softening and dilatation of cervix before mechanical cervical dilatation. SIDE EFFECTS Jaundice, headache, myalgia, pharyngitis, sinusitis. DRUG INTERACTION Pioglitazone is known to interact with other drugs like adrenaline, baclofen, budesonide, carbamazepine, clozapine, diazoxide, gemfibrozil, ginkgo biloba extract, ginseng extract, lovastatin, octreotide (Acetate), olanzapine, phenobarbitone, phenytoin (Na), rifabutin, risperidone, sotalol (HCl). Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required. MECHANISM OF ACTION Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. Pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis.